New data, generated by Daniel Weinberger and colleagues, at the National Institutes of Health, Bethesda, have indicated that in healthy individuals, variation in a gene known as AKT1 affects the structure and function of part of the brain that is dysfunctional in individuals with schizophrenia. Specifically, in healthy individuals, one particular AKT1 variant was associated with impaired cognition (an impaired ability to process information), something that is markedly affected in individuals with schizophrenia. In addition, the same AKT1 variant was associated with decreased grey-matter volume in the frontostriatal region of the brain, which is dysfunctional in individuals with schizophrenia. Further analysis indicated that the AKT1 variant was associated with an increased risk of schizophrenia and the therapeutic implications of this, as well as the other results of the study, are discussed in an accompanying commentary by Alexander Arguello and Joseph Gogos, at Columbia University College of Physicians and Surgeons, New York.
TITLE: Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans
Daniel R. Weinberger
National Institutes of Health, Bethesda, Maryland, USA.
Phone: (301) 402-7564; Fax: (301) 480-7795; E-mail: email@example.com.
View the PDF of this article at: https://www.the-jci.org/article.php?id=34725
TITLE: A signaling pathway AKTing up in schizophrenia
Joseph A. Gogos
Columbia University College of Physicians and Surgeons, New York, New York, USA.
Phone: (212) 305-0744; Fax: (212) 342-1801; Email: firstname.lastname@example.org.
View the PDF of this article at: https://www.the-jci.org/article.php?id=35931
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.